NasdaqGS:LIVN - アナリストの将来予測と過去の財務データ ( )USD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2026	1,350	117	299	N/A	9
12/31/2025	1,279	92	476	N/A	9
12/31/2024	1,216	39	729	N/A	9
3/31/2024	1,185	-32	30	64	N/A
12/31/2023	1,154	18	40	75	N/A
9/30/2023	1,118	3	8	40	N/A
6/30/2023	1,085	-97	29	57	N/A
3/31/2023	1,045	-82	36	65	N/A
12/31/2022	1,022	-86	43	70	N/A
9/30/2022	1,017	-93	60	85	N/A
6/30/2022	1,018	-29	51	73	N/A
3/31/2022	1,028	-102	86	109	N/A
12/31/2021	1,035	-136	77	103	N/A
9/30/2021	1,035	-414	82	106	N/A
6/30/2021	1,022	-385	59	91	N/A
3/31/2021	939	-417	11	46	N/A
12/31/2020	934	-347	-114	-79	N/A
9/30/2020	952	-208	-150	-114	N/A
6/30/2020	981	-161	-234	-199	N/A
3/31/2020	1,076	-102	-230	-199	N/A
12/31/2019	1,084	-158	-116	-91	N/A
9/30/2019	1,094	-222	-106	-73	N/A
6/30/2019	1,097	-260	19	55	N/A
3/31/2019	1,107	-211	63	102	N/A
12/31/2018	1,107	-178	82	120	N/A
9/30/2018	1,088	0	82	117	N/A
6/30/2018	1,068	33	76	108	N/A
3/31/2018	1,036	59	47	79	N/A
12/31/2017	1,012	54	N/A	91	N/A
9/30/2017	795	121	N/A	114	N/A
6/30/2017	840	92	N/A	109	N/A
3/31/2017	905	55	N/A	114	N/A
12/31/2016	965	2	N/A	90	N/A
12/31/2015	545	-22	N/A	-14	N/A
10/18/2015	295	14	N/A	87	N/A
7/24/2015	301	57	N/A	80	N/A
4/24/2015	292	58	N/A	80	N/A
1/23/2015	292	66	N/A	80	N/A
10/24/2014	288	63	N/A	75	N/A
7/25/2014	285	60	N/A	63	N/A
4/25/2014	282	55	N/A	54	N/A
1/24/2014	276	48	N/A	61	N/A
10/25/2013	270	47	N/A	67	N/A
7/26/2013	263	47	N/A	74	N/A

アナリストによる今後の成長予測

収入対貯蓄率: LIVNは今後 3 年間で収益性が向上すると予測されており、これは貯蓄率 ( 2.4% ) よりも高い成長率であると考えられます。

収益対市場: LIVN今後 3 年間で収益性が向上すると予想されており、これは市場平均を上回る成長と考えられます。

高成長収益: LIVN今後 3 年以内に収益を上げることが予想されます。

収益対市場: LIVNの収益 ( 4.6% ) US市場 ( 8.7% ) よりも低い成長が予測されています。

高い収益成長: LIVNの収益 ( 4.6% ) 20%よりも低い成長が予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: LIVNの自己資本利益率は、3年後には低くなると予測されています ( 12.7 %)。

LivaNova 将来の成長

Future 基準チェック /36

主要情報

今後の成長に関する最新情報

LivaNova PLC Provides Earnings Guidance for the Full-Year 2024

Consensus EPS estimates fall by 12%, revenue upgraded

Livanova plc Provides Revenue Guidance for the Full-Year 2023

Price target increased by 7.7% to US$65.33

LivaNova PLC Provides Financial Guidance for the Full Year 2023

LivaNova PLC Provides Earnings Guidance for the Full Year 2023

Recent updates

LivaNova PLC to Report Q2, 2024 Results on Jul 31, 2024

Daniel Jeffrey Moore Resigns as Director of LivaNova PLC

Is LivaNova PLC (NASDAQ:LIVN) Trading At A 31% Discount?

LivaNova PLC Provides Update on Recover Clinical Study Evaluating Vns Therapy for Treatment-Resistant Depression in Unipolar Patients

Independent Director notifies of intention to sell stock

LivaNova: Focus Is Paying Off

Now 21% undervalued

LivaNova PLC Provides Earnings Guidance for the Full-Year 2024

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

LivaNova PLC Announces Ahmet Tezel, Ph.D., as Chief Innovation Officer

LivaNova PLC, Annual General Meeting, Jun 11, 2024

These Return Metrics Don't Make LivaNova (NASDAQ:LIVN) Look Too Strong

Chief Financial Officer exercised options and sold US$353k worth of stock

LivaNova PLC to Report Q1, 2024 Results on May 01, 2024

Now 21% overvalued after recent price rise

LivaNova PLC Announces a Positive Predictive Outcome of Trial Success in its OSPREY Clinical Study for Moderate to Severe Obstructive Sleep Apnea

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Consensus EPS estimates fall by 12%, revenue upgraded

Now 20% overvalued after recent price rise

Livanova plc Announces Impairment Charges for the Three Month Ended December 31, 2023

LivaNova PLC Announces CEO Changes, Effective on March 1, 2024

Is It Time To Consider Buying LivaNova PLC (NASDAQ:LIVN)?

A Look At The Intrinsic Value Of LivaNova PLC (NASDAQ:LIVN)

LivaNova PLC to Report Q4, 2023 Results on Feb 21, 2024

LivaNova PLC's (NASDAQ:LIVN) Business And Shares Still Trailing The Industry

LivaNova (NASDAQ:LIVN) Could Be At Risk Of Shrinking As A Company

We Think LivaNova's (NASDAQ:LIVN) Profit Is Only A Baseline For What They Can Achieve

New minor risk - Earnings quality

Livanova plc Provides Revenue Guidance for the Full-Year 2023

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

At US$47.94, Is LivaNova PLC (NASDAQ:LIVN) Worth Looking At Closely?

LivaNova PLC Announces Board Changes

Are Investors Undervaluing LivaNova PLC (NASDAQ:LIVN) By 44%?

Marco Dolci to Retire as President of Cardiopulmonary Business Unit of LivaNova PLC on December 31, 2023

LivaNova PLC to Report Q3, 2023 Results on Nov 01, 2023

LivaNova Unveils Essenz In-Line Blood Monitor with U.S. FDA 510(k) Clearance and CE Mark

Price target increased by 7.7% to US$65.33

LivaNova PLC Provides Financial Guidance for the Full Year 2023

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Capital Allocation Trends At LivaNova (NASDAQ:LIVN) Aren't Ideal

Should You Investigate LivaNova PLC (NASDAQ:LIVN) At US$51.43?

LivaNova PLC to Report Q2, 2023 Results on Jul 26, 2023

LivaNova PLC Announces 150th Bipolar Depression Patient Randomized in Recover Clinical Study

An Intrinsic Calculation For LivaNova PLC (NASDAQ:LIVN) Suggests It's 37% Undervalued

LivaNova PLC Provides Earnings Guidance for the Full Year 2023

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Price target decreased by 8.1% to US$62.25

Investors Could Be Concerned With LivaNova's (NASDAQ:LIVN) Returns On Capital

CEO & Director exercised options and sold US$432k worth of stock

What Does LivaNova PLC's (NASDAQ:LIVN) Share Price Indicate?

CEO & Director exercised options and sold US$805k worth of stock

Full year 2022 earnings released: US$1.61 loss per share (vs US$2.68 loss in FY 2021)

Estimating The Fair Value Of LivaNova PLC (NASDAQ:LIVN)

LivaNova PLC Initiates Limited Commercial Release in Europe of the Essenz Perfusion System for Cardiopulmonary Bypass Procedures

LivaNova Launches SenTiva DUO

LivaNova PLC to Report Q4, 2022 Results on Feb 22, 2023

Returns At LivaNova (NASDAQ:LIVN) Are On The Way Up

Forecast breakeven date pushed back to 2023

Forecast breakeven date pushed back to 2023

Price target decreased to US$73.71

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

LivaNova PLC Announces Management Changes

Is There Now An Opportunity In LivaNova PLC (NASDAQ:LIVN)?

LivaNova Loses Profit Momentum On Higher R&D Expense

Price target decreased to US$79.57

LivaNova PLC (NASDAQ:LIVN) Shares Could Be 30% Below Their Intrinsic Value Estimate

FDA labels recall of blood bypass pump systems by LivaNova as most serious

LivaNova PLC to Report Q3, 2022 Results on Nov 02, 2022

Now 21% undervalued after recent price drop